Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies
A reversible cancer drug reaches reliable, safe blood levels at a standard dose across diverse patients with minimal drug interactions requiring adjustment.
A two-compartment PK model was developed for nemtabrutinib (reversible BTK inhibitor) using data from 578 patients in Phase 1/2 BELLWAVE studies, confirming 65mg daily for CLL/SLL monotherapy through positive exposure-efficacy trends and acceptably low exposure-safety signals. Intrinsic factors (age, weight, hepatic/renal impairment) and drug interactions (CYP3A4 modulators, acid reducers) had no clinically meaningful impact on PK (<4%).
What the study was
- Study design
- Population PK model + exposure-response analysis (retrospective analysis of Phase 1/2 trial data)
- Population
- CLL/SLL and other hematologic malignancy patients on nemtabrutinib Phase 1/2 BELLWAVE trials
- Sample size
- 578
- Category
- Drug Development
- Maturity
- Validated
- Journal
- CPT: Pharmacometrics & Systems Pharmacology
Why it surfaced
Nemtabrutinib is a promising non-covalent (reversible) BTK inhibitor with activity against C481S-resistant CLL; large PK dataset (N=578) supporting dose selection is clinically relevant for the drug development pipeline.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.